USPTO serial 98081112
T-BRIDGE
Reviewed by CopyMark Law Group
- Filing date
- Status date
- Registration date
- Feb 11, 2025
- Examiner
- ANDERSON, DANIELLE LYNN
- Law office
- FILE REPOSITORY (FRANCONIA)
What this means
Status 700 means the trademark is registered and active on the Principal Register. You have nationwide rights for the listed goods and services and may use ®. Section 8 maintenance is due between years five and six. Calendar Section 8 between years five and six, and consider trademark monitoring.
Need help with T-BRIDGE?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Stacy J. Grossman
Stacy J. Grossman SGIP500 Mamaroneck Avenue, Suite 320Harrison, NY 10528United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical and biological pharmaceutical preparations for medical purposes, namely, for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; chemical preparations for use in DNA analysis for medical purposes; DNA synthesis inhibitors for medical purposes, namely, pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; biological preparations for the treatment of cancer; biological preparations for the treatment of viral and bacterial infections; biological preparations for the treatment of autoimmune diseases; biological preparations for medical use for the treatment of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; immunotherapeutic drugs namely, pharmaceutical preparations for protection from and prevention of viral and bacterial infections, cancer, inflammation, infectious diseases and non-infectious diseases, namely, musculoskeletal, cardiovascular, cardiopulmonary, oncological, neurological, dermatological, genitourinary, sexual dysfunction, hepatological, ophthalmic, respiratory, gastrointestinal, hormonal, psychiatric and immune system diseases and disorders; reagents for medical use; diagnostic preparations for medical use; diagnostic reagents for medical use; preparations for detecting genetic predispositions for medical purposes | ACTIVE | — |
| 042 | Scientific and technological services, namely, scientific research and development in the field of pharmaceuticals for genome engineering and biopharmaceutical drug development for protection from infections, cancer, disease or inflammation; technical research in the field of pharmaceutical studies; industrial analysis and industrial research services in the field of pharmaceuticals and genome engineering; research in the field of DNA repair technology; design and development of computer hardware and software; genetic microbiology and microbiome research for scientific research purposes; scientific research in the field of genetics and genetic engineering; clinical research in the field of pharmaceuticals, biopharmaceutical drug development and genome engineering for protection and prevention from infections, cancer, disease or inflammation; scientific research in the nature of conducting clinical trials for others; pharmaceutical research and development; development of pharmaceutical preparations and medicines; research and development services in the field of antibiotics; research and development of microorganisms and cells in the nature of guided nuclease-based biocides; scientific research in the nature of conducting clinical trials for pharmaceutical products for others; bacteriological research; scientific research for medical purposes in the field of viruses and viral diseases; biological research; scientific screening and assaying being drug screening for scientific research purposes; chemical analysis; chemical research; DNA screening for scientific research purposes; genetic testing of laboratory animals for research purposes; biochemical engineering services being biochemical research and development; providing medical and scientific research information about the results of clinical trials for pharmaceutical products; providing medical and scientific research information in the field of pharmaceuticals and clinical trials; providing scientific research information in the field of pharmaceuticals and scientific research consulting in the field of pharmaceuticals | ACTIVE | — |
| 044 | Medical services; diagnostic and prognostic medical services; veterinary services; medical analysis services relating to the treatment of persons; pharmaceutical advice; medical and health care services relating to DNA, genetics, and genetic pathogen testing for diagnostic or treatment purposes; medical screening and assaying in the nature of medical laboratory analysis services relating to the treatment of persons; DNA screening for medical purposes | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
- Other trademarks owned by T-Therapeutics Limited
- Other trademarks owned by T-Therapeutics Limited
- Other trademarks owned by T-Therapeutics Limited
- Other trademarks in Class 005
- Other trademarks in Class 042
- Other trademarks in Class 044
- Similar marks named T-BRIDGE
- Recently changed USPTO trademarks
- Recently filed trademarks
- Browse all trademark records
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Apr 28, 2025 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Apr 28, 2025 | ARAA | ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Apr 28, 2025 | REAP | TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED | — |
| Apr 28, 2025 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Apr 28, 2025 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Feb 11, 2025 | NRCC | NOTICE OF REGISTRATION CONFIRMATION EMAILED | — |
| Feb 11, 2025 | R.PR | REGISTERED-PRINCIPAL REGISTER | Your trademark is registered on the Principal Register — the strongest form of federal trademark protection. You may use the ® symbol for the covered goods and services. Maintenance filings (Section 8 and renewals) are required to keep the registration alive. |
| Dec 24, 2024 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Dec 24, 2024 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Dec 18, 2024 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Nov 26, 2024 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 22, 2024 | XAEC | EXAMINER'S AMENDMENT ENTERED | — |
| Nov 22, 2024 | GNEN | NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED | — |
| Nov 22, 2024 | GNEA | EXAMINERS AMENDMENT E-MAILED | — |
| Nov 22, 2024 | CNEA | EXAMINERS AMENDMENT -WRITTEN | — |
| Nov 13, 2024 | GNFN | NOTIFICATION OF FINAL REFUSAL EMAILED | — |
| Nov 13, 2024 | GNFR | FINAL REFUSAL E-MAILED | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Nov 13, 2024 | CNFR | FINAL REFUSAL WRITTEN | A final Office Action (final refusal) means the examining attorney is maintaining at least one refusal and your options are narrower. You can file a response addressing the refusal, appeal to the Trademark Trial and Appeal Board, or let the application abandon. |
| Oct 9, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 9, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 9, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Jul 10, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 10, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jul 10, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 11, 2024 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Jun 11, 2024 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Jun 11, 2024 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 31, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| May 31, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| May 31, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 27, 2024 | TCCA | TEAS CHANGE OF CORRESPONDENCE RECEIVED | — |
| Mar 27, 2024 | CHAN | APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED | — |
| Mar 27, 2024 | COAR | TEAS CHANGE OF OWNER ADDRESS RECEIVED | — |
| Mar 23, 2024 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 23, 2024 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 23, 2024 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Mar 20, 2024 | DOCK | ASSIGNED TO EXAMINER | — |
| Aug 10, 2023 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Jul 15, 2023 | NWAP | NEW APPLICATION ENTERED | — |